Clinical Trial Search Results

Filter Results

Age group

Category

Primary purpose

Study type

Location

Search results

You can use the filters to refine your search.

Displaying 1 - 19 of 19

Open Actively Recruiting

Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable/unablatable). Brachytherapy, also known as internal radiation therapy, temporarily introduces a radiation source into or near the tumor to eradicate the tumor cells. Giving brachytherapy may potentially reduce the size of the kidney cancer mass that would otherwise not be amenable to surgical management and translate into lower risk of spread.

Phase: Phase I/II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Albert Chang
Open Actively Recruiting

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Open Actively Recruiting

Study of Kidney Tumors in Younger Patients

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Phase: N/A
Gender: All
Age Group: Children
Contact: Roshani Tasker
Open Actively Recruiting

A Study to Collect Blood Specimens at UCLA in Order to Establish New Immunotherapy for the Treatment of Kidney Cancer

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Phase: N/A
Age Group: Adults
Contact: MARGARET BRADLEY
Open Actively Recruiting

Understanding cardiovascular complications of kidney disease

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: All
Contact: Shilpa Sharma
Investigator:
Shilpa Sharma
Open Actively Recruiting

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE/translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: All
Contact: Mikayla Marvis Henderson
Open Actively Recruiting

Kidney Transplantation in Recipients and Donors with HIV: Long Term Follow up Study

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Rosemary Silva-Garcia
Open Actively Recruiting

New Ways to Test Patients for Kidney and/or Pancreas Transplant Rejection

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: MEGAN LLAMAS
Investigator:
Elaine Reed
Open Actively Recruiting

Validation of a Clinical Biomarker and a Novel Point-of-Care Device for Diabetic Kidney Disease

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Susanne Nicholas
Open Actively Recruiting

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Ankush Sachdeva
Open Actively Recruiting

SPECT/CT for the Characterization of Renal Masses

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Phase: N/A
Gender: All
Age Group: Adults
Contact: MARGARET BRADLEY
Open Actively Recruiting

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Phase: Phase II
Primary Purpose: Treatment
Gender: Female
Age Group: Adults
Contact: Jenny Lester
Open Actively Recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 2 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Shenetra Walker
Open Actively Recruiting

Study of MT-5111 in HER2-positive Solid Tumors

This will be a Phase 1b, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) in subjects with HER2-positive solid tumors

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Lisa Yonemoto
Open Actively Recruiting

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.

Phase: Phase III
Primary Purpose: Treatment
Gender: Female
Age Group: Adults
Contact: Jenny Lester
Open Actively Recruiting

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma 5. Small cell lung cancer 6. Urothelial carcinoma

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Lisa Yonemoto
Open Actively Recruiting

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

The purpose of this research study is to find out if the study drug, ALT-803, plus BCG can stop the growth of tumor in patients with non-muscle invasive bladder cancer whose tumor persisted after treatment with BCG. The sponsor also wish to collect some other information that will help them to improve the way study drug is given to patients.

In this research study, ALT-803 will be tested with BCG.

Patient will have a complete physical exam and vital signs including height, weight, heart and breathing rate, blood pressure and temperature will be checked. About two teaspoons of blood will be collected for testing the functions of patient's kidneys, liver and other organs and for blood cell counts. We will also collect urine for routine urine tests. An electrocardiogram (EKG) will be run to test electrical activity of patient's heart. The patient's lung functions will be examined if it is indicated, and will need to have a biopsy of patient's tumor tissue within 6 weeks of study entry to check the status of the disease. We also need to collect some tissue from these biopsies. The tissue may be analyzed for genes, gene products, proteins, or makers involved in cancer, interleukin response or cell death. The tissue from patient's biopsies that are collected for testing will be analyzed and stored for possible future analysis. Results from these screening tests will be used by the study doctor to find out if the patient qualifies for the research study. If the patient is a woman who can have children, we will collect another teaspoon of blood for a pregnancy test. The study doctor or study staff will tell the patient if the pregnancy test results are positive. The results of the pregnancy test must be negative in order for you to be in the study. We will enroll the patient and schedule their visits to receive the study treatment within 14 days. If the screening tests show that the patient is not eligible to continue in the research study, then the patient may not take part.

Patient's participation in the study will include one cycle of study treatment consisting of six weekly doses of BCG plus ALT-803 study drug and every 3 months visits to evaluate their response to the study treatment. Participants will receive 4 cycles of 3 weekly doses of BCG plus ALT-803 every 3 months if there is no tumor growth. Participants will receive another cycle of study treatment consisting of six weekly doses of BCG plus ALT-803 if there is a decrease in amount of cancer (residual tumor) at 3 months, followed by 4 cycles of 3 weekly doses of BCG plus ALT-803 every 3 months if there is no tumor growth in follow ups. If there is no decrease in the amount of cancer in after one cycle of treatment (6 weeks), patients will not receive more doses of study treatment.

Patient will be closely monitored during the entire treatment period. This study will last as long as patient does not have unacceptable side effects. After the patient completes the study treatment period, if they received at least one dose of study treatment, we will continue to monitor and follow the patients disease and health status every 3 months during years 1 and 2 by scheduled office visits

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Investigator: Karim Chamie, MD
Open Actively Recruiting

Tagraxofusp (SL-401) in Patients With CMML or MF

This drug is directed towards subjects with Myeloproliferative Neoplasms. The goal of this research study is to find the safest highest dose of investigatory drug SL-401 that can be given to patients with myeloproliferative neoplasms. This study will also look at how SL-401 stops or slows cancer cell growth and how SL-401 enters and leaves the body. This study will also look at certain proteins in the blood and the bone marrow and how the amounts of them might change after receiving SL-401, or might be related to how well SL-401 does or does not function against the cancer. SL-401 is an investigational medication. This means that SL-401 is still being studied. It is not approved by the United States Food and Drug Administration (FDA). The FDA allows SL-401 to be used only in clinical studies such as this one. It is anticipated that each patient may be in the study for about 6 ½ months, although the amount of time that each patient will participate will vary, depending on potential side effects of the drug and the growth or shrinkage of the cancer. \n\n There are 2 stages involved with this research study. Stage 1 of the study is the dose escalation portion to understand the highest dose of SL-401 that may be given safely. The study doctor will monitor how patients are feeling (and laboratory tests will be taken which indicate how well blood, liver and kidneys are working) and will work with the study sponsor before additional patients are enrolled at higher doses. Stage 2 of the study will test the highest dose of SL-401 that can be administered safely, as determined during stage 1 of the study, or a lower dose if it can be determined that such a dose has a higher chance of controlling the cancer without causing side effects. During both Stages 1 and 2, the effects of SL-401 on the cancer will also be studied, as well as how SL-401 enters and leaves the body.

Phase: Phase I/II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Bruck Habtemariam
Open Actively Recruiting

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours.

To characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: CHRISTOPHER LIM
Investigator: Lee S. Rosen, MD